Skip Navigation
Skip to contents

CPP : Cardiovascular Prevention and Pharmacotherapy

Sumissioin : submit your manuscript
SEARCH
Search

Previous issues

Page Path
HOME > Browse articles > Previous issues
3 Previous issues
Filter
Filter
Article category
Keywords
Authors
Funded articles
Volume 2(4); October 2020
Prev issue Next issue
Special Articles
Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction
Eui-Soon Kim, Jong-Chan Youn, Sang Hong Baek
Cardiovasc Prev Pharmacother. 2020;2(4):113-133.   Published online October 31, 2020
DOI: https://doi.org/10.36011/cpp.2020.2.e17
  • 9,153 View
  • 148 Download
  • 12 Citations
Abstract PDF
Heart failure (HF) is an important cardiovascular disease because of the increasing prevalence, high morbidity and mortality, and rapid expansion of health care costs. Over the past decades, efforts have been made to modify the prognosis of patients with HF. Regarding HF with reduced ejection fraction (HFrEF), several drugs have shown to improve mortality and morbidity, based on large-scale randomized controlled trials, leading to a critical paradigm shift in its pharmacological treatment. The paradigm of HFrEF pathophysiology has shifted from cardiorenal disease to hemodynamic changes, and neurohormonal activation is currently considered the prime pathophysiological mechanism of HFrEF. This review summarizes evidence on the pharmacological management of HFrEF derived from major randomized controlled trials, which have accomplished improvements in survival benefits.

Citations

Citations to this article as recorded by  
  • Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea
    Eui-Soon Kim, Sun-Kyeong Park, Jong-Chan Youn, Hye Sun Lee, Hae-Young Lee, Hyun-Jai Cho, Jin-Oh Choi, Eun-Seok Jeon, Sang Eun Lee, Min-Seok Kim, Jae-Joong Kim, Kyung-Kuk Hwang, Myeong-Chan Cho, Shung Chull Chae, Seok-Min Kang, Jin Joo Park, Dong-Ju Choi,
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea
    Eui-Soon Kim, Sun-Kyeong Park, Daniel Sung-ho Cho, Jong-Chan Youn, Hye Sun Lee, Hae-Young Lee, Hyun-Jai Cho, Jin-Oh Choi, Eun-Seok Jeon, Sang Eun Lee, Min-Seok Kim, Jae-Joong Kim, Kyung-Kuk Hwang, Myeong-Chan Cho, Shung Chull Chae, Seok-Min Kang, Jin Joo
    American Journal of Cardiovascular Drugs.2024; 24(2): 313.     CrossRef
  • Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
    Jong-Chan Youn, Darae Kim, Jae Yeong Cho, Dong-Hyuk Cho, Sang Min Park, Mi-Hyang Jung, Junho Hyun, Hyun-Jai Cho, Seong-Mi Park, Jin-Oh Choi, Wook-Jin Chung, Byung-Su Yoo, Seok-Min Kang
    Korean Circulation Journal.2023; 53(4): 217.     CrossRef
  • Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
    Jong-Chan Youn, Darae Kim, Jae Yeong Cho, Dong-Hyuk Cho, Sang Min Park, Mi-Hyang Jung, Junho Hyun, Hyun-Jai Cho, Seong-Mi Park, Jin-Oh Choi, Wook-Jin Chung, Byung-Su Yoo, Seok-Min Kang
    International Journal of Heart Failure.2023; 5(2): 66.     CrossRef
  • Post-transplantation outcomes of sensitized patients receiving durable mechanical circulatory support
    Jong-Chan Youn, Xiaohai Zhang, Keith Nishihara, In-Cheol Kim, Sang Hong Baek, Osamu Seguchi, Evan P. Kransdorf, David H. Chang, Michelle M. Kittleson, Jignesh K. Patel, Robert M. Cole, Jaime D. Moriguchi, Danny Ramzy, Fardad Esmailian, Jon A. Kobashigawa
    The Journal of Heart and Lung Transplantation.2022; 41(3): 365.     CrossRef
  • Treatment of heart failure with a preserved ejection fraction
    Yuran Ahn, Jong-Chan Youn
    Journal of the Korean Medical Association.2022; 65(1): 18.     CrossRef
  • Multimodal Imaging and Biomarkers in Cardiac Amyloidosis
    Mi-Hyang Jung, Suyon Chang, Eun Ji Han, Jong-Chan Youn
    Diagnostics.2022; 12(3): 627.     CrossRef
  • Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy
    In-Cheol Kim, Jong-Chan Youn, Se Yong Jang, Sang Eun Lee, Hyun-Jai Cho, Jin-Oh Choi, Ju-Hee Lee, Kyung-Hee Kim, Sun Hwa Lee, Kye Hun Kim, Jong Min Lee, Byung-Su Yoo, Byung-Su Yoo, Se Yong Jang, Jong Min Lee, In-Cheol Kim, Jin-Oh Choi, Hyun-Jai Cho, Sang E
    Scientific Reports.2022;[Epub]     CrossRef
  • A dose–response relationship of renin–angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study
    Kyung An Kim, Eui-Soon Kim, Jong-Chan Youn, Hye Sun Lee, Soyoung Jeon, Hae-Young Lee, Hyun-Jai Cho, Jin-Oh Choi, Eun-Seok Jeon, Sang Eun Lee, Min-Seok Kim, Jae-Joong Kim, Kyung-Kuk Hwang, Myeong-Chan Cho, Shung Chull Chae, Seok-Min Kang, Dong-Ju Choi, Byu
    European Heart Journal - Cardiovascular Pharmacotherapy.2022; 8(6): 587.     CrossRef
  • Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation
    Jong-Chan Youn, Darae Kim, In-Cheol Kim, Hye Sun Lee, Jin-Oh Choi, Eun-Seok Jeon, Keith Nishihara, Evan P. Kransdorf, David H. Chang, Michelle M. Kittleson, Jignesh K. Patel, Danny Ramzy, Fardad Esmailian, Jon A. Kobashigawa
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Pathophysiology of Heart Failure with Preserved Ejection Fraction
    Jong-Chan Youn, Yuran Ahn, Hae Ok Jung
    Heart Failure Clinics.2021; 17(3): 327.     CrossRef
  • Heart failure risk in younger adults needing more attention
    Jong-Chan Youn, Sang Hong Baek
    International Journal of Cardiology.2021; 344: 135.     CrossRef
Barriers in Salt Reduction Strategies: Time to Acting for the Future
Yong-Jae Kim
Cardiovasc Prev Pharmacother. 2020;2(4):134-141.   Published online October 31, 2020
DOI: https://doi.org/10.36011/cpp.2020.2.e16
  • 3,031 View
  • 47 Download
Abstract PDF
Salt reduction is important for reducing hypertension and the risk of cardiovascular events and stroke. Despite knowledge about the ill consequences, many people continue to consume high levels of salt in their diet. This paper introduces salt-reducing programs for individual, population, and country-level strategies to reduce salt intake. To effectively decrease salt intake, it is necessary to reduce the consumption of high-salt foods and replace high-salt seasonings with low-salt alternatives. Thus, healthcare professionals must effectively provide information on salt-reduction for patients with hypertension. Social strategies, such as voluntary sodium reduction targets for the food industry, are necessary to promote population strategies for salt reduction. In this paper, we examine a brief report on new salt intake values based on chronic disease risk reduction and explain the utilization of mobile health technologies to reduce salt consumption. Considering the relationship between dietary salt intake and the risk of chronic disease, ways to remove the barriers to strategies for salt reduction should be considered, as it is the most effective way for the prevention and control of hypertension and cardiovascular disease in the future.
Logistic Regression and Least Absolute Shrinkage and Selection Operator
Hyunyong Lee, Hun-Sung Kim
Cardiovasc Prev Pharmacother. 2020;2(4):142-146.   Published online October 31, 2020
DOI: https://doi.org/10.36011/cpp.2020.2.e15
  • 3,807 View
  • 36 Download
  • 1 Citations
Abstract PDF
Logistic regression, a model that forms a binary dependent variable and one or more independent variable(s), is used especially in epidemiological studies. By understanding the logistic model and its applications, such as odds ratio (OR) and performance efficiency, the concept of logistic regression can be easily grasped. The purpose of this article is to 1) introduce logistic regression, including odds and OR, 2) present predictive efficiency, such as area under the curve, and 3) explain the caution of logistic regression analysis.

Citations

Citations to this article as recorded by  
  • Perceptron: Basic Principles of Deep Neural Networks
    Eung-Hee Kim, Hun-Sung Kim
    Cardiovascular Prevention and Pharmacotherapy.2021; 3(3): 64.     CrossRef

CPP : Cardiovascular Prevention and Pharmacotherapy
TOP